BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 27486888)

  • 1. Screening of Variations in CD22 Gene in Children with B-Precursor Acute Lymphoblastic Leukemia.
    Aslar Oner D; Akin DF; Sipahi K; Mumcuoglu M; Ezer U; Kürekci AE; Akar N
    Genet Test Mol Biomarkers; 2016 Sep; 20(9):552-5. PubMed ID: 27486888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia.
    Uckun FM; Goodman P; Ma H; Dibirdik I; Qazi S
    Proc Natl Acad Sci U S A; 2010 Sep; 107(39):16852-7. PubMed ID: 20841423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD22ΔE12 as a molecular target for corrective repair using RNA trans-splicing: anti-leukemic activity of a rationally designed RNA trans-splicing molecule.
    Uckun FM; Qazi S; Ma H; Reaman GH; Mitchell LG
    Integr Biol (Camb); 2015 Feb; 7(2):237-49. PubMed ID: 25567759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia.
    Ryland GL; Barraclough A; Fong CY; Fleming S; Bajel A; Hofmann O; Westerman D; Grimmond S; Blombery P
    Br J Haematol; 2020 Oct; 191(1):123-126. PubMed ID: 32648276
    [No Abstract]   [Full Text] [Related]  

  • 5. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases.
    Raponi S; De Propris MS; Intoppa S; Milani ML; Vitale A; Elia L; Perbellini O; Pizzolo G; Foá R; Guarini A
    Leuk Lymphoma; 2011 Jun; 52(6):1098-107. PubMed ID: 21348573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of CD22 expression in acute lymphoblastic leukemia.
    Shah NN; Stevenson MS; Yuan CM; Richards K; Delbrook C; Kreitman RJ; Pastan I; Wayne AS
    Pediatr Blood Cancer; 2015 Jun; 62(6):964-9. PubMed ID: 25728039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of a new human pre-B acute lymphoblastic leukemia cell line (KMO-90) with 1;19 translocation carrying p53 gene alterations.
    Sotomatsu M; Hayashi Y; Kawamura M; Yugami S; Shitara T
    Leukemia; 1993 Oct; 7(10):1615-20. PubMed ID: 8412323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deficiency of the adaptor SLP-65 in pre-B-cell acute lymphoblastic leukaemia.
    Jumaa H; Bossaller L; Portugal K; Storch B; Lotz M; Flemming A; Schrappe M; Postila V; Riikonen P; Pelkonen J; Niemeyer CM; Reth M
    Nature; 2003 May; 423(6938):452-6. PubMed ID: 12761551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia.
    Goodman PA; Wood CM; Vassilev A; Mao C; Uckun FM
    Oncogene; 2001 Jul; 20(30):3969-78. PubMed ID: 11494125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia.
    Rosenthal J; Naqvi AS; Luo M; Wertheim G; Paessler M; Thomas-Tikhonenko A; Rheingold SR; Pillai V
    Am J Hematol; 2018 Nov; 93(11):E352-E355. PubMed ID: 30058145
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of Recurrent Refractory Pediatric Pre-B Acute Lymphoblastic Leukemia Using Inotuzumab Ozogamicin Monotherapy Resulting in CD22 Antigen Expression Loss as a Mechanism of Therapy Resistance.
    Paul MR; Wong V; Aristizabal P; Kuo DJ
    J Pediatr Hematol Oncol; 2019 Nov; 41(8):e546-e549. PubMed ID: 30807395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD22 Exon 12 deletion is a characteristic genetic defect of therapy-refractory clones in paediatric acute lymphoblastic leukaemia.
    Ma H; Qazi S; Ozer Z; Gaynon P; Reaman GH; Uckun FM
    Br J Haematol; 2012 Jan; 156(1):89-98. PubMed ID: 22017452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of aberrantly spliced oncogenic ikaros isoforms in childhood acute lymphoblastic leukemia.
    Sun L; Goodman PA; Wood CM; Crotty ML; Sensel M; Sather H; Navara C; Nachman J; Steinherz PG; Gaynon PS; Seibel N; Vassilev A; Juran BD; Reaman GH; Uckun FM
    J Clin Oncol; 1999 Dec; 17(12):3753-66. PubMed ID: 10577847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombination activating gene-1 (RAG-1) expression in all differentiation stages of B-lineage precursor acute lymphoblastic leukemia.
    Umiel T; Pattengale P; Weinberg K
    Leukemia; 1993 Mar; 7(3):435-40. PubMed ID: 8445948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNMT3A mutations and prognostic significance in childhood acute lymphoblastic leukemia.
    Li W; Gao C; Cui L; Liu S; Zhao X; Zhang R; Wu M; Zheng H; Deng G; Li Z; Zhang Q
    Leuk Lymphoma; 2015 Apr; 56(4):1066-71. PubMed ID: 25242092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-exome sequencing of a rare case of familial childhood acute lymphoblastic leukemia reveals putative predisposing mutations in Fanconi anemia genes.
    Spinella JF; Healy J; Saillour V; Richer C; Cassart P; Ouimet M; Sinnett D
    BMC Cancer; 2015 Jul; 15():539. PubMed ID: 26201965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22-positive B-cell acute lymphoblastic leukaemia.
    Calvo C; Cabannes-Hamy A; Adjaoud D; Bruno B; Blanc L; Boissel N; Tabone MD; Willson-Plat G; Villemonteix J; Baruchel A; Brethon B
    Br J Haematol; 2020 Jul; 190(1):e53-e56. PubMed ID: 32424837
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of Polypeptide-based Nanoparticles for Non-viral Delivery of CD22 RNA Trans-splicing Molecule as a New Precision Medicine Candidate Against B-lineage ALL.
    Uckun FM; Mitchell LG; Qazi S; Liu Y; Zheng N; Myers DE; Song Z; Ma H; Cheng J
    EBioMedicine; 2015 Jul; 2(7):649-59. PubMed ID: 26288837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Casitas B lymphoma mutations in childhood acute lymphoblastic leukemia.
    Nicholson L; Knight T; Matheson E; Minto L; Case M; Sanichar M; Bomken S; Vormoor J; Hall A; Irving J
    Genes Chromosomes Cancer; 2012 Mar; 51(3):250-6. PubMed ID: 22072526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial.
    Wayne AS; Kreitman RJ; Findley HW; Lew G; Delbrook C; Steinberg SM; Stetler-Stevenson M; Fitzgerald DJ; Pastan I
    Clin Cancer Res; 2010 Mar; 16(6):1894-903. PubMed ID: 20215554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.